Most of what zinc supplementation reliably achieves is repairing a shortfall, not enhancement beyond normal. Properly formulated lozenges started at the first cold symptom shorten the episode; blood sugar and blood fats improve modestly over months; central retina damage progresses more slowly in those already at risk. Above roughly 40 mg daily, zinc displaces copper. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Plasma zinc | 80–100 µg/dL | Direct status marker; guides corrective versus maintenance dosing |
| Serum copper | 90–120 µg/dL | The most important safety marker; falls before symptoms appear |
| Ceruloplasmin | 22–35 mg/dL | Confirms low copper is true depletion, not assay variation |
| Zinc-to-copper ratio | 0.8–1.2 | The balance matters more than either value alone |
| Complete blood count | Hemoglobin within reference; neutrophils above 1.8 × 10⁹/L | Detects the marrow suppression copper depletion causes |
| Serum ferritin | 50–150 ng/mL (men), 40–100 (women) | Tracks the iron stores sustained zinc intake competes against |
| Alkaline phosphatase | 70–100 U/L | Zinc-dependent enzyme; low-normal values suggest functional shortfall |
| High-sensitivity C-reactive protein | Below 1.0 mg/L | Response marker for inflammation; needed to read zinc and ferritin |
| Glycated hemoglobin | 5.0–5.4% | Response marker where blood-sugar control is the indication |
| High-density lipoprotein cholesterol | Above 50 mg/dL (men), 60 (women) | Detects the lipid change reported at very high zinc doses |
| Prostate-specific antigen | No zinc-specific target; track own baseline and rate of change | For men above 40 mg daily, given the unresolved prostate-cancer signal |
Cadence: Baseline panel before starting, then plasma zinc, copper, ceruloplasmin and complete blood count at 3 months, at 12 months, then every 12 months. Above 40 mg daily, or a corrective dose held beyond 12 weeks: 3-monthly copper and blood count until the dose comes down.